drugset / Trial / NCT04719650

Clinical Pharmacokinetics and Pharmacodynamics Study of Different Doses of Zoledronic Acid

NCT04719650

Phase 4 Unknown 64 enrolled Peking University Third Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

The recommended dosing regimen of zoledronic acid in Chinese osteoporosis patients is completely in accordance with the one of 5 mg per year abroad that based on the dosing regimen in Paget's disease. This dosing regimen lacks the actual supportive clinical data of Chinese patients. In addition, the overall incidence of acute phase response, the main adverse event after the first infusion, in Chinese patients is higher than that in Caucasian patients population. Moreover, the results of the similar drug clinical study in the Japanese patients shown that the purpose of effective treatment for osteoporosis could be achieved with half of the dosage in Caucasian population. Thus, it could be inferred from these that the dosing regimen of zoledronic acid might be inappropriate in Chinese osteoporosis patients. Therefore, the main purpose of this clinical trail is to compare the zoledronic acid pharmacokinetic and pharmacodynamic characteristic of different doses in Chinese postmenopausal subjects with low bone mass or osteoporosis and explore the best dosing regimen in Chinese patients.

Timeline

Start
2021-10
Primary completion
2024-10
Completion
2024-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Zoledronic acid Other / unclassified 1 mg Intravenous
Subject Zoledronic acid Other / unclassified 2.5 mg Intravenous
Subject Zoledronic acid Other / unclassified 5 mg Intravenous